Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in multiple Phase 3 clinical trials for azetukalner in epilepsy and neuropsychiatry indications, with key topline data readouts and NDA submission anticipated in 2026.

• Expanded early-stage pipeline with two novel ion channel modulators for pain, with Phase 1 data expected in 2026 to support Phase 2 studies.

• Raised $242.2 million through ATM offerings, extending cash runway into the second half of 2027.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $586.0 million as of December 31, 2025, down from $754.4 million at year-end 2024; pro forma cash including Q1 2026 ATM proceeds is $716.0 million.

• Research and development expenses rose to $300.9 million for 2025, up from $210.4 million in 2024, driven by Phase 3 studies and increased personnel costs.

• General and administrative expenses increased to $79.6 million for 2025 from $68.9 million in 2024, mainly due to higher headcount and professional fees.

• Net loss for 2025 was $345.9 million, compared to $234.3 million in 2024, reflecting higher R&D and G&A expenses and lower interest income.

• Net loss per share was $4.36 for 2025, compared to $3.01 in 2024.

Outlook and guidance

• Topline data from Phase 3 X-TOLE2 study in focal onset seizures expected in March 2026, with NDA submission planned for the second half of 2026.

• Phase 3 X-NOVA2 study in major depressive disorder expected to deliver topline data in H1 2027.

• Cash runway projected to fund operations into the second half of 2027.